1. Home
  2. ALMU vs CHRS Comparison

ALMU vs CHRS Comparison

Compare ALMU & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aeluma Inc.

ALMU

Aeluma Inc.

HOLD

Current Price

$21.79

Market Cap

257.6M

Sector

Technology

ML Signal

HOLD

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

HOLD

Current Price

$1.60

Market Cap

296.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALMU
CHRS
Founded
2019
2010
Country
United States
United States
Employees
14
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
257.6M
296.8M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
ALMU
CHRS
Price
$21.79
$1.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$24.67
$5.51
AVG Volume (30 Days)
1.8M
1.3M
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
472.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$17.49
$73.08
Revenue Next Year
$60.61
$30.94
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.20
$0.72
52 Week High
$31.79
$2.62

Technical Indicators

Market Signals
Indicator
ALMU
CHRS
Relative Strength Index (RSI) 48.68 44.31
Support Level $14.16 $1.55
Resistance Level $22.12 $1.80
Average True Range (ATR) 3.44 0.11
MACD -0.65 0.00
Stochastic Oscillator 22.23 20.93

Price Performance

Historical Comparison
ALMU
CHRS

About ALMU Aeluma Inc.

Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: